Clinical Trial Update: ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of ADXS31-142 alone and with pembrolizumab in previously treated metastatic castration-resistant prostate cancer completed; results posted in 20…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ADXS31-142
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Advaxis, Inc. | Conditions: Cancer, Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-02-20